Status: Recruiting
Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
Participants needed: 200
Trial details
Phase: Phase 4Age: 18-100Biological sex: AllType: InterventionalSponsor: Alexion Pharmaceuticals, Inc.Updated: Jan 7, 2026Locations: 16
Eligibility criteria
Naive participants: newly diagnosed with ATTR-CM and no prior treatment with dru... [+6]
Have confirmed diagnosis of AL amyloidosis [+7]